Issues

Clinical panel sequencing analysis of endometrial cancers (EC) identified differences in the prevalence of histologic types, molecular subtypes, and genetic alterations by self-identified race/genetic ancestry, providing insights into EC disparities.

Combined clinical, radiographic, and molecular analyses demonstrate the efficacy of ONC201 in H3K27M-mutant diffuse midline glioma, as ONC201 was shown to disrupt integrated metabolic and epigenetic pathways and reverse pathognomonic H3K27me3 reduction.

NeoCOAST, the first neoadjuvant platform trial of novel immuno-oncology combinations, demonstrates that combined therapies improve responses and immunologic cell activation compared to durvalumab (anti–PD-L1) monotherapy in resectable non–small cell lung cancer.

Targeting the PRMT5/MTA complex selectively inhibits growth of MTAP-deleted preclinical cancer models and demonstrates preliminary clinical activity in MTAP-deleted cancers.

The preclinical profile of STX-478, a mutant-selective, allosteric PI3Kα inhibitor, demonstrates its potential to expand the limited therapeutic window of approved inhibitors and significantly improve outcomes in patients with PI3Kα-mutant cancers.

BCL2 inhibition in type 1 conventional dendritic cells (cDC1) activates the cGAS/STING/type 1 IFN pathway and exerts cDC1-dependent, T cell–mediated anticancer effects, unveiling BCL2 as an endogenous checkpoint of cDC1.

Oncogenesis arises from hijacking a subset of transposable elements active in pluripotent stem cells into regulatory elements for lineage-specific transcription factors, such as the androgen receptor in prostate cancer.